Will JAK1/2 inhibitors change the standard of care for myelofibrosis?.

Author: Chul Won JUNG ¹
Author Information

1. Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Publication Type:Review
MeSH: Standard of Care
From:Korean Journal of Hematology 2012;47(4):241-242
CountryRepublic of Korea
Language:English
Abstract: No abstract available.